- Home
- CAPL vs ALLO Comparison
CAPL vs ALLO Comparison
Compare CAPL & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CAPL | ALLO |
|---|---|---|
| Founded | 1992 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 858.5M | 707.6M |
| IPO Year | 2012 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CAPL | ALLO |
|---|---|---|
| Price | $22.02 | $2.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $8.35 |
| AVG Volume (30 Days) | 44.1K | ★ 6.9M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.96% | N/A |
| EPS Growth | ★ 96.15 | 34.09 |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $1,869,806,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.80 | $142,416.42 |
| P/E Ratio | $83.54 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.61 | $0.99 |
| 52 Week High | $23.34 | $4.46 |
Technical Indicators
Market Signals| Indicator | CAPL | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 49.89 | 48.86 |
| Support Level | $21.53 | $1.85 |
| Resistance Level | $23.01 | $2.36 |
| Average True Range (ATR) | 0.56 | 0.13 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 49.83 | 49.03 |
Price Performance
Historical ComparisonAbout CAPL CrossAmerica Partners
CrossAmerica Partners LP is engaged in the wholesale distribution of motor fuel and the ownership and leasing of real estate used in the retail distribution of motor fuel. The company operates through two business segments, namely Wholesale and Retail. The Wholesale segment is a key revenue driver and includes the wholesale distribution of motor fuel to lessee dealers, independent dealers, commission agents, DMS, Circle K, and through company-operated retail sites. The Retail segment includes the sale of convenience merchandise items, the retail sale of motor fuel at company-operated retail sites, and the retail sale of motor fuel at retail sites operated by commission agents.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).